TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06272682

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systemic bethametasone injection
Description: betamethasone intramuscular injection in the treatment of carpal tunnel syndrome

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local bethametasone injection
Description: Local betamethasone injection under ultrasound in the carpal tunnel, in the treatment of carpal tunnel syndrome
Study: NCT05079438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dendrobium Huoshanense Suppository
Description: 1.7g rectal administration per day for 5 weeks
Study: NCT04970706

Intervention type: PROCEDURE
Intervention: ACL reconstruction
Description: All patients will undergo a standardized single-bundle technique with a hamstring or bone-patellar tendon-bone autograft.
Study: NCT05992077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Daclatasvir
Description: Patients with a weight \> 25 kg will be treated with a sofosbuvir/daclatasvir combination for 12 weeks with adult dose (400/60 mg), children with a weight between 14 and 25 kg will be treated with the same sofosbuvir/daclatasvir combination with the half adult dose (200/30 mg) for 12 weeks.
Study: NCT05596981

Intervention type: DRUG
Intervention: Sorafenib
Description: The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
Study: NCT05617872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinegar 20ml
Description: Inject 20ml vinegar (5% acetic acid solution) into duodenum and collect the pancreatic juice for 15 minutes via EUS, changing the collection bottle every 5 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (NaCl 0,9 %) (placebo)
Description: Inject 20ml normal saline solution into duodenum and collect the pancreatic juice for 15 minutes via EUS, changing the collection bottle every 5 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinegar 40ml
Description: Inject 40ml vinegar (5% acetic acid solution) into duodenum and collect the pancreatic juice for 15 minutes via EUS, changing the collection bottle every 5 minutes.
Study: NCT06219577

Intervention type: DRUG
Group type: OTHER
Intervention: Systane Complete Multi-Dose PF
Description: Eyedrop

Intervention type: DRUG
Group type: OTHER
Intervention: Walgreen's Lubricant Balance
Description: Eyedrop
Study: NCT06223932

Intervention type: DRUG
Intervention: Molnupiravir
Description: COVID-19 diagnosed patients receiving molnupiravir will be evaluated to show if Molnupiravir is effective in reducing the combined outcome of hospitalization/death due to COVID-19 in the first 28 days when used in real life.
Study: NCT05011695

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Description: The 1st group will be given ESWT therapy, the 2nd group will be given transverse friction massage, and the 3rd group will be given exercises that are used in the treatment of plantar fasciitis and have proven effectiveness

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Description: The 1st group will be given ESWT therapy, the 2nd group will be given transverse friction massage, and the 3rd group will be given exercises that are used in the treatment of plantar fasciitis and have proven effectiveness

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Description: The 1st group will be given ESWT therapy, the 2nd group will be given transverse friction massage, and the 3rd group will be given exercises that are used in the treatment of plantar fasciitis and have proven effectiveness
Study: NCT05430776

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photobimodulation
Description: laser therapy application

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photobimodulation
Description: laser therapy application
Study: NCT05053763

Intervention type: DRUG
Group type: OTHER
Intervention: Remimazolam
Description: The study was carried out using a biased coin design up-and-down sequential method, where the dose of remimazolam administered to each patient depended on the response of the previous one with success/failure duodenoscopy insertion during ERCP are required for reliable estimates. The first patient was tested at 0.2mg/kg remimazolam (0.025mg/kg as a step size). Duodenoscopy insertion was conducted when MOAA/S≤1.The response of the patients to the duodenoscopy insertion during ERCP was categorized as either 'success (no movement)' or 'failure (movement). if a patient had a failure duodenoscopy insertion, the dose of remimazolam was increased by 0.025mg/kg in the next subject. If a patient had a successful duodenoscopy insertion the next subject was randomised to receive either a lower dose (with a decrement of 0.025mg/kg), with a probability of b = 0.11, or the same dose, with a probability of 1-b = 0.89.

Intervention type: DRUG
Group type: OTHER
Intervention: Remimazolam
Description: The study was carried out using a biased coin design up-and-down sequential method, where the dose of remimazolam administered to each patient depended on the response of the previous one with success/failure duodenoscopy insertion during ERCP are required for reliable estimates. The first patient was tested at 0.2mg/kg remimazolam (0.025mg/kg as a step size). Duodenoscopy insertion was conducted when MOAA/S≤1.The response of the patients to the duodenoscopy insertion during ERCP was categorized as either 'success (no movement)' or 'failure (movement). if a patient had a failure duodenoscopy insertion, the dose of remimazolam was increased by 0.025mg/kg in the next subject. If a patient had a successful duodenoscopy insertion the next subject was randomised to receive either a lower dose (with a decrement of 0.025mg/kg), with a probability of b = 0.11, or the same dose, with a probability of 1-b = 0.89.
Study: NCT05103592

Intervention type: DIAGNOSTIC_TEST
Intervention: Tartrate- resistant Acid Phosphatase marker
Description: marker could be diagnostic for osteoporosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Tartrate- resistant Acid Phosphatase marker
Description: marker could be diagnostic for osteoporosis
Study: NCT04739475

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non Surgical Periodontal Therapy
Description: Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing.
Study: NCT06381141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLN-619
Description: Anti-MICA/MICB monoclonal antibody
Study: NCT06380608

Intervention type: PROCEDURE
Intervention: Local anesthesia
Description: Patients who will undergo a dental surgery under local anesthesia

Intervention type: PROCEDURE
Intervention: General anesthesia
Description: Patients who will undergo a dental surgery under general anesthesia
Study: NCT05535062

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation
Description: the administration of a series of magnetic stimuli to the brain for the purpose of altering brain function

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation
Description: the administration of a series of magnetic stimuli to the brain for the purpose of altering brain function
Study: NCT06027710

Intervention type: PROCEDURE
Intervention: Extensive alveolar ridge augmentation with allogeneic bone blocks; dental implant insertion in allogeneic bone graft
Description: Alveolar ridge augmentation procedure for extensive bone defect rehabilitation in the upper and/or lower jaw allogeneic bone blocks; dental implant insertion in allogeneic bone graft for oral rehabilitation after 6 month of healing

Intervention type: PROCEDURE
Intervention: Extensive alveolar ridge augmentation with allogeneic bone blocks; dental implant insertion in allogeneic bone graft
Description: Alveolar ridge augmentation procedure for extensive bone defect rehabilitation in the upper and/or lower jaw allogeneic bone blocks; dental implant insertion in allogeneic bone graft for oral rehabilitation after 6 month of healing
Study: NCT04731116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Oral Cannabidiol 150 mg twice daily during 14 days
Study: NCT05223322

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Taking Charge during Treatment (TCT) Intervention
Description: CT is a 16-20week intervention that promotes adoption of the ACSM exercise guidelines for cancer survivors during treatment, including regular moderate to vigorous physical activity (150 minutes per week of moderate activity or 75 minutes per week of vigorous activity) and a minimum of twice weekly resistance training (RT) minutes during CTx and after. Program components include (1) a binder of information, (2) weekly coaching, (3) 2-4x weekly text messaging and (4) exercise supplies. The TCT program is grounded in Social Cognitive Theory.
Study: NCT04904718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DreaMed Advisor Pro
Description: Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data consisting of glucose levels, insulin delivery history and meal consumption reported
Study: NCT05418647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high dialysate Na
Description: high dialysate sodium (Na = 141 mmol/L) for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low dialysate Na
Description: low dialysate sodium (Na = 136 mmol/L) for 8 weeks
Study: NCT05025345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tecnis Eyhance
Description: Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis 1 piece IOL
Description: Control intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
Study: NCT06685445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Continue Erector Spinae Plane Block
Description: For the block, the ultrasound (USG)probe will be placed longitudinally 2-3 cm lateral to the transverse process of the T4-5 vertebra. The erector spinae muscle will be visualized above the hyperechoic transverse process. Using in plane technique, the block needle will be advanced in the cranio-caudal direction and 5 ml of saline will be injected under the erector spinae muscle to confirm the block site. After the block site is confirmed, 30 ml of 0.25% bupivacaine (Marcain 0.5%® AstraZeneca, England) will be administered. The block catheter (Perifix® Braun, Germany) will then be inserted to block area

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Continue Erector Spinae Plane Block + Serratus Anterior Plane Block
Description: For ESPB, USG probe will be placed longitudinally 2-3 cm lateral to the transverse process of the T4-5 vertebra. The erector spinae muscle will be visualized above the hyperechoic transverse process. Using in plane technique, the block needle will be advanced in the cranio-caudal direction and 5 ml of saline will be injected under the erector spinae muscle to confirm the block site and 30 ml of 0.25% bupivacaine (Marcain®) will be administered. The block catheter (Perifix®) will be inserted. For SAPB, the USG probe will be placed parasagittal to the mid-axillary line at the 5th-6th rib level and the anechoic shadow of the costa together with the latissumus dorsi and serratus anterior muscles will be visualized. Then using in plane technique, the block needle will be advanced in the cranio-caudal direction and 5 ml of saline will be injected under the serratus anterior muscle and the block site will be confirmed and 30 ml of 0.25% bupivacaine will be administered.
Study: NCT05842291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS with short inter-session interval
Description: Participants in this group will receive ten sessions per day of 1800 pulses per session, at an inter-session interval of 20 min for 5 days. The individualized target will be generated using the personalized Brain Functional Sectors (pBFS) method.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS with short inter-session interval
Description: Participants in this group will receive ten sessions per day of 1800 pulses per session, at an inter-session interval of 20 min for 5 days, using sham stimulation coils that comprehensively mimic the active condition. The individualized target will be generated using the personalized Brain Functional Sectors (pBFS) method.
Study: NCT05669313

Intervention type: DRUG
Intervention: Rivaroxaban 15 MG
Description: Rivaroxaban 15 mg after inclusion and on the morning after inclusion, i.e., before blood sampling
Study: NCT05842291

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS with long inter-session interval
Description: Participants in this group will receive ten sessions per day of 1800 pulses per session, at an inter-session interval of 50 min for 5 days. The individualized target will be generated using the personalized Brain Functional Sectors (pBFS) method.
Study: NCT05378152

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pipelle biopsy catheter
Description: A speculum will be inserted into the vagina. A Pipelle biopsy catheter will be inserted through the cervix up to the fundus of the uterus. The internal piston will be withdrawn to create negative pressure. The catheter will be moved back and forth and rotated to collect the biopsy. The catheter will then be removed, followed by the speculum. The sample will be sent to the laboratory for assessment.
Study: NCT06033456

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency stellate ganglion block using ultrasound guidance (SGB)
Description: Visualization of C6-C7 level will be targeted under fluoroscopic posterior-anterior (PA) guidance. Skin will be infiltrated with 1% lidocaine using a 25-gauge needle. Next, the RF needle will be inserted under a trajectory approach toward the target. Then, with ultrasound guidance, using a superficial linear ultrasound probe to guide further needle penetration so that the needle-tip will lie anterior to the longus colli muscle, the exclusion of vascular structures will be confirmed by duplex(8).~Then, 5 to 1 mL of omnipaque dye (iohexol) will be injected. Subsequently, a 100 mm length Baily RF electrode will be inserted and connected to the generator. The RF needle will be positioned alongside the stellate ganglion in the thermal RF technique. With repeated sensory and motor stimulation before RF lesioning

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency thoracic (T2, T3) paravertebral block under fluoroscopic guidance (TPVB)
Description: Radiofrequency sympathectomy will be performed with the patient in the prone position. Under fluoroscopic guidance, the T2, T3 vertebral bodies will be identified in an anteroposterior view. For radiofrequency sympathectomy, 10 cm curved, sharp radiofrequency insulated needle with an active tip of 10 mm, needle entry will be performed, and the final placement of the needle tip will be located at the posterior third of the vertebral body in lateral view and just lateral to the body in the anteroposterior view. Once the correct position is confirmed, 0.5 to 1 ml of Omnipaque will be injected, then a 10 cm electrode will be introduced through the RF needle. Before lesioning, a sensory and motor test stimulation is performed to verify the location.
Study: NCT05378152

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: A speculum is inserted into the vagina and then removed
Study: NCT06033456

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined radiofrequency of stellate ganglion block plus thoracic T2, T3 paravertebral block
Description: Combination between radiofrequency of stellate ganglion block and thoracic T2, T3 paravertebral block.
Study: NCT05257187

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcervical foley catheter
Description: The foley catheter is inserted manually by an obstetric provider through the cervix and inflated with 60cc of saline. Once in the correct position, the catheter is inflated, which puts pressure on the cervix, allowing it to release hormones that soften the cervix and help the cervix to open. The foley catheter can be left in place up to 12 hours but typically will fall out when the cervix is dilated to 3-4 centimeters.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcervical foley catheter
Description: The foley catheter is inserted manually by an obstetric provider through the cervix and inflated with 60cc of saline. Once in the correct position, the catheter is inflated, which puts pressure on the cervix, allowing it to release hormones that soften the cervix and help the cervix to open. The foley catheter can be left in place up to 12 hours but typically will fall out when the cervix is dilated to 3-4 centimeters.
Study: NCT05802485

Intervention type: OTHER
Group type: OTHER
Intervention: collection of blood and tumor samples
Description: The study consists of the collection of a 25 ml blood sample:~* Before the start of treatment~* Approximately 2 months after the start of induction chemotherapy~* At the end of induction chemotherapy~* Prior to local treatment (radiotherapy, surgery)~* At the time of tumor progression~At the time of collection of tumor material:~* During the initial diagnostic biopsy~* On the operating room in case of surgery~* During a tumor biopsy in case of recurrence or progression (optional) and a questionnaire evaluating the patient's spontaneous physical activities.
Study: NCT05430295

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification
Description: cataract extraction followed by bilateral implantation of Eyhance intraocular lens in 10 patients and bilateral implantation of Tecnis 1 piece IOL in 10 patients

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification
Description: cataract extraction followed by bilateral implantation of Eyhance intraocular lens in 10 patients and bilateral implantation of Tecnis 1 piece IOL in 10 patients

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: monofocal intraocular lens implantation
Description: implantation of monofocal intraocular lens in the capsular bag at the end of phacoemulsification surgery
Study: NCT05340127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CEREBO®
Description: Usability Study
Study: NCT06454240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lunsekimig
Description: Pharmaceutical form:solution for injection-Route of administration:subcutaneous
Study: NCT05911997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTC 01
Description: Slurry to be administered via colonoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTC 01
Description: Slurry to be administered via colonoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Description: Stool from a healthy donor is blended with salt water and made into a liquid solution rich in bacteria. This solution is sprayed into the recipient's colon during a colonoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation (FMT)
Description: Stool from a healthy donor is blended with salt water and made into a liquid solution rich in bacteria. This solution is sprayed into the recipient's colon during a colonoscopy
Study: NCT06454240

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:solution for injection-Route of administration:subcutaneous
Study: NCT05430295

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: monofocal intraocular lens implantation
Description: implantation of monofocal intraocular lens in the capsular bag at the end of phacoemulsification surgery
Study: NCT05890261

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold water-perfused cooling garment
Description: Two types of cooling garments will be used. One is a cooling vest and the other includes cooling pants.
Study: NCT05829421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Impairment-specific occupational therapy (OT) intervention
Description: In parallel with standard practice, patients receive an OT intervention adapted to the specific underlying cognitive impairments that are likely to disturb their performance of ADLs.~The intervention is individualised through a 3-step process: a) a list of dysfunctional ADL process skills is forwarded by the OT to the neuropsychologist (NP), b) the NP identifies the cognitive impairments which are most likely to cause the dysfunctional ADL process skills through a cognitive assessment, c) based on the identified cognitive impairments, the NP and the OT select in collaboration the cognitive strategies that are most likely to benefit the individual patient from a pre-prepared intervention manual. Because of the large heterogeneity in how cognitive impairments impact on ADL performance, the exact way of implementing the selected cognitive strategies into the practice of the individual patient is left to the OT´s clinical judgement.
Study: NCT06099652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 611 300 mg Q2W
Description: 611 subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 611 450 mg Q2W
Description: 611 subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: placebo subcutaneous (SC) injection
Study: NCT04738539

Intervention type: DRUG
Intervention: Contrast Enhanced Voiding Urosonography with Urodynamic Testing
Description: We will be using contrast enhanced voiding urosonography to image urodynamic testing on patients with neurogenic bladder.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urodynamic Testing
Description: We will be using contrast enhanced voiding urosonography to image urodynamic testing on patients with neurogenic bladder.
Study: NCT05361330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shuganjieyu capsule
Description: 2 capsules each time, twice per day. According to the study progress, the intervention can be adjusted to 4 capsules each time, twice per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoxetine
Description: Medication in basic study period: Fluoxetine (20 mg, once a day) Medication in the expanded study period: After 8 weeks of basic study period, if the reduction rate of HAMD-17 total scores is below 50 %, for the treatment group, the dosage of Fluoxetine will be adjusted to 40 mg / time, once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Medication in basic study period: Fluoxetine (20 mg, once a day) Medication in the expanded study period: After 8 weeks of basic study period, if the reduction rate of HAMD-17 total scores is below 50 %, for the treatment group, the dosage of Fluoxetine will be adjusted to 40 mg / time, once a day.